2023 World Conference on Lung Cancer (Posters)-EP10.01. Retrospective Study on Outcomes and Treatment Options for Patients with NSCLC Progression after Treatment with Durvalumab

EP10.01. Retrospective Study on Outcomes and Treatment Options for Patients with NSCLC Progression after Treatment with Durvalumab - PDF(Abstract)

Back to course

Pdf Summary

This study examined treatment options and outcomes for patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after receiving durvalumab, a form of immunotherapy. The study was conducted retrospectively and included 37 patients who had previously been diagnosed with unresectable stage III NSCLC and received durvalumab after concurrent chemoradiation therapy. After progression, the patients received various treatments including immunotherapy, chemotherapy, targeted therapy, or a combination of these. <br /><br />The results showed that 41% of patients remained stable, 13% had disease progression, 27% died, 8% enrolled in hospice care, and 11% had unknown outcomes. The study also found that patients treated with immunotherapy alone or in combination with chemotherapy had improved overall survival (OS) and second progression-free survival (PFS). However, the management of patients following treatment for stage III NSCLC varied significantly, indicating a need for further research to optimize treatment strategies and improve outcomes. <br /><br />The study was based on data from the PACIFIC trial, which demonstrated the efficacy of durvalumab as consolidation therapy for unresectable locally advanced stage III NSCLC. The trial showed improved overall survival and progression-free survival rates compared to placebo. However, treatment options for patients who progress after receiving durvalumab are currently limited or not well defined. This study contributes to the understanding of treatment options and outcomes for these patients, emphasizing the need for further research in this area. <br /><br />In conclusion, this retrospective study evaluated treatment regimens for patients with NSCLC who progressed after receiving durvalumab. The results suggest that immunotherapy alone or combined with chemotherapy may improve survival outcomes. However, more research is needed to establish optimized treatment strategies and improve overall outcomes for patients with metastatic NSCLC.

Asset Subtitle

Bushra Shariff

Meta Tag

Speaker Bushra Shariff

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

metastatic non-small cell lung cancer

NSCLC

durvalumab

immunotherapy

treatment options

outcomes

chemotherapy

targeted therapy

overall survival

progression-free survival